Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review
Pier-Valerio Mari, Lorenzo Carriera, Angela Saviano, Alberto Ricci, Angelo Coppola, Simone Ielo, Roberto Lipsi, Meridiana Dodaj, Francesco Gennari, Mario Gullà, Davide Stivalini, Maria Gabriella Pellegrino, Alessio Migneco, Eugenio De Corso, Veronica Ojetti · 2026
Read Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review by Pier-Valerio Mari, Lorenzo Carriera, Angela Saviano, Alberto Ricci, Angelo Coppola, Simone Ielo, Roberto Lipsi, Meridiana Dodaj, Francesco Gennari, Mario Gullà, Davide Stivalini, Maria Gabriella Pellegrino, Alessio Migneco, Eugenio De Corso, Veronica Ojetti (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13179912.txt.
Description
Pier-Valerio Mari and co-authors review how a drug called dupilumab shifts the body's microbes in a paper from 2026. The drug blocks two signals, IL-4 and IL-13, that drive type 2 inflammation. It treats diseases such as atopic dermatitis and sinus disease with polyps.
The team gathered fifteen studies, most on skin disease. Across skin studies, the drug cut a harmful germ and raised microbe diversity. Nose studies hinted at shifts toward healthier microbe mixes. Gut data were thin and less clear. The review maps what is known by body site and flags where more work is needed.
Catalog record
| CREATOR | Pier-Valerio Mari, Lorenzo Carriera, Angela Saviano, Alberto Ricci, Angelo Coppola, Simone Ielo, Roberto Lipsi, Meridiana Dodaj, Francesco Gennari, Mario Gullà, Davide Stivalini, Maria Gabriella Pellegrino, Alessio Migneco, Eugenio De Corso, Veronica Ojetti |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |